Schedule 13D ownership disclosure

AXOVANT SCIENCES LTD

Security class unavailable · CUSIP: G0750W104

Event date: 2017-06-12

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
75,000,000
Percent of class
69.8000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000903423-17-000418
Form type
SC 13D/A
Filer
Sio Gene Therapies Inc.
CIK
CIK 1636050
Filed
Jun 14, 2017
Reporting period
Jun 12, 2017
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub